Cybin Inc
CYBN
View Detailed Chart
6.070USD
+0.120+2.02%
Close 11/06, 16:00（ET）Quotes delayed by 15 min
139.81MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.02%
5 Days
-15.46%
1 Month
-5.60%
6 Months
-0.16%
Year to Date
-31.18%
1 Year
-38.93%
View Detailed Chart
TradingKey Stock Score of Cybin Inc
Currency: USD Updated: 2025-11-06Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Cybin Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
84.833
Target Price
+1325.77%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Cybin Inc Highlights
StrengthsRisks
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Overvalued
The company’s latest PE is -1.34, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 9.89M shares, decreasing 88.50% quarter-over-quarter.
Cybin Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Cybin Inc Info
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.
Ticker SymbolCYBN
CompanyCybin Inc
CEOMr. Eric How-Lun So
Websitehttps://www.cybin.com
Related Instruments
+1.26%
+0.52%
+1.05%
+3.23%
+0.85%
+1.65%
-1.33%
-4.02%
+0.67%
+0.98%
+1.00%
+1.70%
-0.18%
+0.34%
+0.88%
+1.07%
0.00%
+0.42%
+1.36%
-0.77%Popular Symbols
